Caroline Sabin

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
    Susie Huntington
    Centre for Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
    BMC Infect Dis 14:127. 2014
  2. pmc When should antiretroviral therapy be started in HIV-positive persons?
    Caroline A Sabin
    Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus Rowland Hill Street, London NW3 2PF UK
    F1000 Med Rep 2:81. 2010
  3. pmc Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    BMC Med 11:251. 2013
  4. pmc Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study
    Signe W Worm
    Research Department of Infection and Population Health, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    BMC Infect Dis 13:471. 2013
  5. doi request reprint Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL, London, United Kingdom
    J Acquir Immune Defic Syndr 63:456-63. 2013
  6. pmc Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women
    Susie E Huntington
    Research Department of Infection and Population Health, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    BMC Med Res Methodol 12:110. 2012
  7. ncbi request reprint Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
    Loveleen Bansi
    HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
    J Acquir Immune Defic Syndr 53:633-9. 2010
  8. doi request reprint Data linkage reduces loss to follow-up in an observational HIV cohort study
    Teresa Hill
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    J Clin Epidemiol 63:1101-9. 2010
  9. pmc Factors influencing lopinavir and atazanavir plasma concentration
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    J Antimicrob Chemother 65:129-37. 2010
  10. ncbi request reprint Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors
    David Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:771-7. 2008

Collaborators

Detail Information

Publications53

  1. pmc Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
    Susie Huntington
    Centre for Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
    BMC Infect Dis 14:127. 2014
    ..Short-term zidovudine monotherapy (ZDVm) remains an option for some pregnant HIV-positive women not requiring treatment for their own health but may affect treatment responses once antiretroviral therapy (ART) is subsequently started...
  2. pmc When should antiretroviral therapy be started in HIV-positive persons?
    Caroline A Sabin
    Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus Rowland Hill Street, London NW3 2PF UK
    F1000 Med Rep 2:81. 2010
    ..Several large cohort studies have published findings that contribute to the debate, although conclusions vary and results from these studies may be subject to bias...
  3. pmc Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    BMC Med 11:251. 2013
    ..Thus, further improvements in LE may now only be possible if some of the other underlying issues (for example, modification of lifestyle or behavioral factors) are tackled...
  4. pmc Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study
    Signe W Worm
    Research Department of Infection and Population Health, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    BMC Infect Dis 13:471. 2013
    ..Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004-2010, and described subsequent mortality and predictors of these...
  5. doi request reprint Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL, London, United Kingdom
    J Acquir Immune Defic Syndr 63:456-63. 2013
    ..We investigated associations between ALT levels and the risk of various cardiovascular and cerebrovascular outcomes in a large cohort study of HIV-positive individuals...
  6. pmc Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women
    Susie E Huntington
    Research Department of Infection and Population Health, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    BMC Med Res Methodol 12:110. 2012
    ..A methodology was developed to find and match records for women reported to both studies thereby obtaining clinical and treatment data on pregnant HIV-positive women not available from either dataset alone...
  7. ncbi request reprint Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
    Loveleen Bansi
    HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
    J Acquir Immune Defic Syndr 53:633-9. 2010
    ..The study aim was to determine how resistance testing influences outcome of first-line highly active antiretroviral therapy (HAART) in routine practice in the United Kingdom...
  8. doi request reprint Data linkage reduces loss to follow-up in an observational HIV cohort study
    Teresa Hill
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    J Clin Epidemiol 63:1101-9. 2010
    ..To ascertain the degree of loss to follow-up in a cohort and to identify its predictors...
  9. pmc Factors influencing lopinavir and atazanavir plasma concentration
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    J Antimicrob Chemother 65:129-37. 2010
    ..The aim of this study was to evaluate which demographic factors and concomitant drugs are associated with lopinavir and atazanavir plasma concentration...
  10. ncbi request reprint Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors
    David Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:771-7. 2008
    ..These changes might be expected to affect the prevalence and patterns of protease resistance in the population of patients who experience treatment failure...
  11. doi request reprint Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study
    Tristan J Barber
    St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 16:805-14. 2011
    ..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort...
  12. doi request reprint Virological response to initial antiretroviral regimens containing abacavir or tenofovir
    Loveleen Bansi
    Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom
    J Infect Dis 200:710-4. 2009
    ..88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART...
  13. doi request reprint Biomarkers to monitor safety in people on art and risk of mortality
    Loveleen Bansi
    UCL Medical School, Royal Free Campus, London, UK
    J Acquir Immune Defic Syndr 60:51-8. 2012
    ..Using time-updated laboratory measurements, we use several methods to derive a score that can be used to identify individuals at high risk of mortality...
  14. doi request reprint Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study
    Loveleen Bansi
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    J Acquir Immune Defic Syndr 52:391-6. 2009
    ..However, the definition of an ALT flare is arbitrary and the extent to which such increases represent normal fluctuations has not been explored...
  15. doi request reprint Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study
    R J C Gilson
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    HIV Med 11:152-60. 2010
    ..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes...
  16. ncbi request reprint Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy
    Krishnan Bhaskaran
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    Ann Neurol 63:213-21. 2008
    ..We therefore aimed to assess changes over calendar time in the risk for HIV-associated dementia (HIV-D), and factors associated with HIV-D risk...
  17. doi request reprint The impact of HIV drug resistance testing on changes to treatment
    Loveleen Bansi
    Research Department of Infection and Population Health, UCL Medical School, UK
    AIDS 25:603-10. 2011
    ..We investigate changes made to therapy after a resistance test result and identify factors associated with switching regimen...
  18. doi request reprint Late diagnosis in the HAART era: proposed common definitions and associations with mortality
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    AIDS 24:723-7. 2010
    ....
  19. pmc Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals
    Stephane Hue
    UCL MRC Centre for Medical Molecular Virology, University College London, Windeyer Building, 46 Cleveland Street, London W1T 4JF, United Kingdom
    J Virol 83:2645-54. 2009
    ..These findings provide new insights for the planning and management of treatment programs in resource-rich and developing countries...
  20. doi request reprint The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
    ..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus...
  21. doi request reprint Risk of tuberculosis following HIV seroconversion in high-income countries
    Sara Lodi
    Clinical Trials Unit, Medical Research Council, London, UK
    Thorax 68:207-13. 2013
    ....
  22. doi request reprint Natural history of HIV-control since seroconversion
    Yoann Madec
    aInstitut Pasteur, Emerging Diseases Epidemiology Unit, Paris bINSERM U1018, Centre de Recherche en Epidémiologie et Santé des Populations, Le Kremlin Bicêtre cFaculté de Médecine Paris Sud, Universite Paris Sud, Paris dDepartment of Public Health, AP HP, Bicetre Hospital, Le Kremlin Bicetre, France eMedical Research Council, Clinical Trials Unit, London, UK fCluster Infectious Diseases, Department of Research, Center for Infection and Immunity Amsterdam CINIMA, Public Health Service, Amsterdam, The Netherlands gResearch Department of Infection and Population Health, UCL Medical School, London, UK hSan Paolo Hospital, Milan, Italy iInternational AIDS Vaccine Initiative, San Francisco, USA jRobert Koch Institut, Berlin, Germany kUlleval Hospital, Oslo, Norway lINSERM U1012, Le Kremlin Bicêtre mDepartment of Internal Medicine, AP HP, Bicetre Hospital, Le Kremlin Bicêtre nUniversité Paris Sud, Paris, France
    AIDS 27:2451-60. 2013
    ..HIV-controllers spontaneously maintain HIV viremia at an undetectable level. We aimed to describe the delay to control from seroconversion, the duration of control, and risk factors for losing control...
  23. doi request reprint The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults
    Nicola E Mackie
    aDepartment of HIV GUM, Imperial College Healthcare NHS Trust bMRC Clinical Trials Unit, London cDepartment of Clinical Virology, Manchester Royal Infirmary, Manchester dResearch Department of Infection and Population Health, UCL Medical School, London eInstitute of Infection and Global Health, University of Liverpool, Liverpool, UK
    AIDS 27:2245-53. 2013
    ....
  24. pmc Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study
    Colette Smith
    Infection and Population Health, University College London, London, UK
    J Int AIDS Soc 17:19512. 2014
    ..We investigated the association between EFV use and completed suicide...
  25. ncbi request reprint Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:675-85. 2008
    ..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine...
  26. doi request reprint Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters
    L Waters
    Department of GU HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, UK
    HIV Med 12:289-98. 2011
    ..We investigated whether adverse responses to highly active antiretroviral therapy (HAART) associated with late HIV presentation are secondary to low CD4 cell count per se or other confounding factors...
  27. doi request reprint Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK
    Julie Fox
    Department of HIV, Guys and St Thomas NHS Trust Kings College London, St Thomas Hospital, London, UK
    AIDS 24:2397-401. 2010
    ..To describe the frequency and risk factors of non-B HIV-1 subtypes in men who have sex with men (MSM) in the UK...
  28. pmc Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women?
    Susie Huntington
    Department of Infection and Population Health, UCL, London, UK
    J Int AIDS Soc 17:19486. 2014
    ..However, the extent to which pregnancy affects the risk of ART-induced hepatotoxicity is unclear since studies in this area have generated conflicting results...
  29. doi request reprint Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study
    Mathias Bruyand
    INSERM, ISPED, Centre INSERM U897 Epidemiologie Biostatistique, Bordeaux, France Copenhagen HIV Programme, Department of Infectious Diseases and Rheumatology, Section 8632, Finsencenteret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Research Department of Infection and Population Health, UCL, London, United Kingdom First Department of Internal Medicine, University Hospital of Cologne, Koln, Germany German Center for Infection research DZIF HIV Epidemiology and Prevention Program, Kirby Institute, UNSW Australia, Sydney, Australia Division of Infectious Diseases and Department of Global Health, Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam, the Netherlands Stichting HIV Monitoring, Amsterdam, The Netherlands Department of Infectious Diseases, St Pierre University Hospital, Brussels, Belgium Infectious Diseases Unit, Department of Health Sciences, San Paolo University Hospital, Milan, Italy Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland and Département de Santé Publique, Hopital de l Archet, CHU de Nice, USA
    J Acquir Immune Defic Syndr 68:568-77. 2015
    ..The association between combination antiretroviral therapy (cART) and cancer risk, especially regimens containing protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs), is unclear...
  30. pmc Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
    Anna Schultze
    Department of Infection and Population Health, University College London, London, UK
    J Int AIDS Soc 17:19737. 2014
    ..We sought to quantify the effect of resistance mutations on CD4 slopes in patients undergoing episodes of viral failure...
  31. pmc Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
    Margaret T May
    aUniversity of Bristol bNorth Bristol NHS Trust, Bristol cPublic Health England dMedical Research Council Clinical Trials Unit eBarts and The London NHS Trust fSouth London Healthcare NHS Trust gSt George s Healthcare NHS Trust hRoyal Free Hampstead NHS Trust, London iUniversity Hospitals of Leicester NHS Trust, Leicester jMortimer Market Centre, University College Medical School, London kSouth Tees Hospital NHS Foundation Trust, Middlesbrough lYork Teaching Hospital NHS Foundation Trust, York mResearch Department of Infection and Population Health, UCL nImperial College Healthcare NHS Foundation Trust oKings College Healthcare NHS Foundation Trust and Kings College London, London pBrighton and Sussex University Hospitals NHS Trust, Brighton qNorth Middlesex University Hospital NHS Trust, London rThe Lothian University Hospitals NHS Trust, Edinburgh sChelsea and Westminster NHS Foundation Trust tHomerton University Hospital NHS Trust, London, UK
    AIDS 28:1193-202. 2014
    ..The objective of this study is to estimate life expectancies of HIV-positive patients conditional on response to antiretroviral therapy (ART)...
  32. doi request reprint Clinical epidemiology of HIV-associated end-stage renal failure in the UK
    Loveleen Bansi
    University College London Medical School, London, UK
    AIDS 23:2517-21. 2009
    ..To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom...
  33. doi request reprint HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
    Daniella N Chilton
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 15:985-91. 2010
    ..We examined the characteristics of HIV-1 drug resistance in antiretroviral treatment (ART)-naive individuals migrating to the UK...
  34. doi request reprint The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy
    C A Sabin
    Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
    HIV Med 10:35-43. 2009
    ....
  35. pmc Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
    Amanda Mocroft
    Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS Med 10:e1001510. 2013
    ..Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality...
  36. doi request reprint British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
    Ian Williams
    University College London, UK
    HIV Med 13:1-85. 2012
    ..They should be read in conjunction with other published BHIVA guidelines...
  37. pmc Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, UK
    BMC Med Res Methodol 12:30. 2012
    ..However estimates of the prevalence of TDR will also be distorted if some ART-experienced patients are misclassified as ART-naïve...
  38. pmc Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception
    Susie E Huntington
    UCL Medical School, Royal Free Campus, UK
    AIDS 25:1647-55. 2011
    ....
  39. pmc Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy
    Sophie Jose
    aResearch Department of Infection and Population Health, UCL bImperial College London Department of Medicine, London cThe Lothian University Hospitals NHS Trust, Edinburgh dSt George s Healthcare NHS Trust, London eBrighton and Sussex University Hospitals NHS Trust, Brighton fKings College Hospital NHS Foundation Trust and King s College London gChelsea and Westminster NHS Foundation Trust, London hNorth Bristol NHS Trust, Bristol iRoyal Free Hampstead NHS Trust, London jSouth Tees Hospital NHS Foundation Trust, Middlesbrough kMortimer Market Centre, University College Medical School, London, UK
    AIDS 28:1333-9. 2014
    ..We compared rates of laboratory-defined adverse events (LDAEs) according to CD4(+) cell count at ART initiation...
  40. doi request reprint The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom
    Hannah Green
    HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
    J Acquir Immune Defic Syndr 49:196-204. 2008
    ..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable...
  41. doi request reprint Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients
    Fowzia Ibrahim
    Department of Renal Sciences, King s College London, London, UK
    Nephrol Dial Transplant 27:2291-7. 2012
    ..It is unknown whether Chronic Kidney Disease Epidemiological Collaboration (CKD-EPI) or Modification of Diet in Renal Disease (MDRD) provide better estimates of glomerular filtration rate (GFR) in this population...
  42. pmc Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study
    David A Kamara
    Research Dept, of Infection and Population Health, University College London, London, United Kingdom
    BMC Nephrol 15:51. 2014
    ..73 m2 (using Cockcroft Gault) in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study from 2004 to 2011...
  43. doi request reprint CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era
    Sara Lodi
    MRC Clinical Trials Unit, London, UK
    AIDS 24:2697-704. 2010
    ..Studies based on seroconverters have increased our understanding of HIV disease. It is not clear, however, whether their disease progression differs from that of the general HIV population, given their reasons for presenting for testing...
  44. ncbi request reprint Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1717-21. 2007
    ..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART...
  45. ncbi request reprint Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom
    Deenan Pillay
    Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
    J Infect Dis 192:967-73. 2005
    ..Method 2 also nearly doubles estimates of numbers of individuals infected with multiclass drug-resistant virus. Our results identify an urgent need for new drugs within existing classes and new classes of antiretroviral therapy...
  46. doi request reprint Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions
    Alison E Brown
    Centre for Infections, Health Protection Agency, University College London, London, UK
    J Infect Dis 199:427-31. 2009
    ..Previous analyses may have incorrectly assigned transmission events to the acutely HIV infected when they were more likely to have occurred during chronic infection...
  47. pmc Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study
    Jemma O'Connor
    Department of Infection and Population Health, UCL, London, UK
    J Int AIDS Soc 17:19527. 2014
    ..It is unclear whether those who have maintained VL suppression for several years will be able to continue to do so, or if rates of VL failure - due to poor adherence, ART interruption and/or resistance - remain at appreciable levels...
  48. ncbi request reprint Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters
    Abdel Babiker
    MRC Clinical Trials Unit, London, United Kingdom
    J Acquir Immune Defic Syndr 32:303-10. 2003
    ..After that time, there is little to be gained in terms of short-term response from initiating HAART before reaching a CD4 count of 200 cells/microL...
  49. ncbi request reprint Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons
    Meghna Ramaswamy
    Department of Virology, Royal Free and University College Medical School, London, UK
    Sex Transm Dis 33:96-101. 2006
    ..The objective of this study was to determine herpes simplex virus type 2 (HSV-2) seroprevalence at HIV-1 diagnosis and seroincidence > or =1 year after HIV-1 diagnosis...
  50. doi request reprint Definition and epidemiology of late presentation in Europe
    Margaret Johnson
    HIV Department, Royal Free Hospital, Hampstead, London, UK
    Antivir Ther 15:3-8. 2010
    ..Standardizing the definition of late presentation will facilitate understanding, clinical research and, ultimately, effective treatment of late-presenting patients...
  51. doi request reprint Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
    Catia Marzolini
    aDivision of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel, Basel, Switzerland bDepartment of Infection and Population Health, University College London, London, UK cDivision of Infectious Diseases, University Hospital of Nantes, Nantes, France dDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK eClinic of Infectious Diseases, University of Modena, Modena, Italy fUniversity Paris Descartes, Paris, France gRadboud University Medical Centre, Nijmegen, the Netherlands hHospital General of Castellon, University of Valencia and University Jaume I, Valencia, Spain iDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland jUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy kDepartment of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark lDepartment of Infectious and Tropical Diseases, HIV Unit, University Hospital Pellegrin, Bordeaux, France mMedical University Innsbruck, Innsbruck, Austria nDepartment of Internal Medicine
    AIDS 29:193-200. 2015
    ..We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients...
  52. ncbi request reprint The changing pattern of bronchoscopy in an HIV-infected population
    Simon Taggart
    Royal Free Hospital HIV Centre, Hampstead, London, UK
    Chest 122:878-85. 2002
    ..This study was performed to identify any changes to our pattern of use of bronchoscopy over the last decade, and how this might relate to the introduction of more effective ARTs to our center in 1996...
  53. ncbi request reprint Differences in presentation and follow-up between HIV-1 antibody positive teenagers and adults: the need for a more focused approach to care?
    Katia Prime
    Mortimer Market Centre, London, UK
    AIDS 17:260-2. 2003
    ..There is an urgent need to examine the reasons for this and adopt strategies to minimize risk-taking behaviour and to improve access to appropriate healthcare...